Indivior PLC Joins the S&P SmallCap 600 Index: A New Chapter in Healthcare Innovation Indivior PLC's recent inclusion in the S&P SmallCap 600 Index marks a significant milestone for the company in the healthcare sector.

Indivior PLC Joins the S&P SmallCap 600 Index: A New Chapter in Healthcare Innovation #USA #Richmond #Indivior #SUBLOCADE #opioid_use_disorder

Indivior Finalizes Settlement with U.S. Department of Justice to Move Forward Indivior PLC has officially settled a legacy matter with the U.S. Department of Justice by paying $295 million, marking a pivotal change for the company.

Indivior Finalizes Settlement with U.S. Department of Justice to Move Forward #United_States #Richmond #Indivior #Opioid_Treatment #Department_of_Justice

Indivior Unveils New Evidence Supporting Treatment Benefits of Buprenorphine at AMCP Nexus 2025 Indivior presented significant findings at AMCP Nexus 2025, highlighting the efficacy and economic advantages of high adherence to monthly injectable buprenorphine in treating opioid use disorder.

Indivior Unveils New Evidence Supporting Treatment Benefits of Buprenorphine at AMCP Nexus 2025 #USA #Richmond #Indivior #opioid_use_disorder #Buprenorphine

#Indivior has agreed to halt all marketing of its #opioidoverdosedrug Opvee in New York after being rapped by the state attorney general for #mispromoting it to health officials.

pharmaphorum.com/news/indivio...

Indivior Announces Strategic Shift to U.S. Domiciliation for Growth and Innovation Indivior PLC has proposed a significant change in its corporate structure, transitioning its domicile from the U.K. to the U.S. to enhance market presence.

Indivior Announces Strategic Shift to U.S. Domiciliation for Growth and Innovation #United_States #Richmond #pharmaceuticals #Indivior #Opioid_Treatment

Big pharma firms have paused nearly £2bn in UK investments this year Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

#lifesciences #biotech #Pharmaceuticals #AstraZeneca #Trump #MSD #EliLilly #drugpricing #ABPI #BristolMyersSquibb #NHS #VPAG #Sanofi #Novartis #BioNTech #Moderna #Haleon #Indivior #VeronaPharma #AdaptimmuneTherapeutics #WorldMeds #GSK #RentschlerBiopharma #Recipharm
zurl.co/3FQOT

Indivior PLC Gears Up for Key Investor Engagements This Fall Indivior PLC announces its participation in significant investor events. Engage with leadership on critical topics in healthcare.

Indivior PLC Gears Up for Key Investor Engagements This Fall #United_States #New_York_City #healthcare #Indivior #OUD_Treatment

Indivior Sets New Financial Expectations After Solid Q2 2025 Performance Indivior PLC announces its Q2 2025 financial results, showcasing a strong net revenue increase and improved guidance for the fiscal year ahead.

Indivior Sets New Financial Expectations After Solid Q2 2025 Performance #United_States #Richmond #Indivior #SUBLOCADE #fiscal_guidance

New Study Highlights Benefits of Extended-Release Buprenorphine for Opioid Use Disorder Recent findings from Indivior's study reveal that extended-release buprenorphine significantly reduces emergency department visits for opioid use disorder, improving patient outcomes.

New Study Highlights Benefits of Extended-Release Buprenorphine for Opioid Use Disorder #United_States #Richmond #Indivior #opioid_use_disorder #Buprenorphine

Indivior Welcomes Vanessa Procter as New Executive VP of Corporate Affairs Indivior PLC has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, bringing 25 years of biopharmaceutical experience to the role.

Indivior Welcomes Vanessa Procter as New Executive VP of Corporate Affairs #United_States #Richmond #Corporate_Affairs #Indivior #Vanessa_Procter

Indivior Grows Its Market Presence with Inclusion in Russell 2000® Index Indivior PLC has officially been added to the U.S. Russell 2000® Index, aligning its capital market presence with its expanding U.S. operations.

Indivior Grows Its Market Presence with Inclusion in Russell 2000® Index #United_States #Richmond #Russell_2000 #Indivior #Opioid_Treatment

Indivior Welcomes Tony Kingsley to its Board as Non-Executive Director Indivior PLC has officially appointed Tony Kingsley as an Independent Non-Executive Director, effective July 1, 2025, enhancing its leadership team.

Indivior Welcomes Tony Kingsley to its Board as Non-Executive Director #United_States #Richmond #Indivior #OUD #Tony_Kingsley

Indivior Unveils New Insights on Buprenorphine Effectiveness for Opioid Use Disorder at CPDD Indivior PLC presents groundbreaking data at CPDD showing that 300 mg of SUBLOCADE may enhance treatment for high fentanyl users suffering from opioid use disorder.

Indivior Unveils New Insights on Buprenorphine Effectiveness for Opioid Use Disorder at CPDD #United_States #Richmond #Indivior #SUBLOCADE #opioid_use_disorder

Click Subscribe #Indivior #StockMarket #FinanceNews #USTrading #LondonStockExchange

Indivior Announces Move to Cancel London Secondary Listing, Focusing on Nasdaq Indivior PLC has declared its plan to cancel its secondary listing on the London Stock Exchange, maintaining its primary listing on Nasdaq. Here's what it means.

Indivior Announces Move to Cancel London Secondary Listing, Focusing on Nasdaq #NASDAQ #United_Kingdom #London_Stock_Exchange #Indivior #Slough

Indivior Set to Engage Investors in Key Upcoming Events Across the U.S. Indivior PLC will be participating in several investor events, including the Jefferies Global Healthcare Conference and other significant gatherings to discuss their initiatives.

Indivior Set to Engage Investors in Key Upcoming Events Across the U.S. #United_States #healthcare #Richmond #investors #Indivior

Click Subscribe #Indivior #StockMarket #Investing #RevenueGrowth #FinancialNews

Indivior Reports Strong Q1 2025 Financial Performance and Future Prospects Indivior PLC reveals its financial results for Q1 2025, showcasing growth and future prospects in the treatment of opioid use disorder.

Indivior Reports Strong Q1 2025 Financial Performance and Future Prospects #United_Kingdom #Richmond #financial_results #Indivior #opioid_use_disorder

Indivior PLC Announces Significant Changes in the Board of Directors to Enhance Management Structure Indivior PLC announces major alterations to its Board of Directors, refining its structure and leadership. Key changes include the appointment of new directors and adjustments in committee leadership.

Indivior PLC Announces Significant Changes in the Board of Directors to Enhance Management Structure #United_States #Richmond #Board_of_Directors #Oaktree_Capital #Indivior

Indivior Welcomes Joe Ciaffoni as New Chief Executive Officer Indivior PLC has appointed Joe Ciaffoni as its new CEO. He brings over 30 years of pharmaceutical experience, promising growth.

Indivior Welcomes Joe Ciaffoni as New Chief Executive Officer #United_States #Richmond #Indivior #Joe_Ciaffoni #Chief_Executive_Officer

Indivior's Latest SUBLOCADE Label Changes Approved by FDA, Revolutionizing Opioid Treatment Indivior's recent FDA approval for SUBLOCADE offers a rapid initiation protocol and flexible injection sites, marking a pivotal step in opioid use disorder treatment.

Indivior's Latest SUBLOCADE Label Changes Approved by FDA, Revolutionizing Opioid Treatment #USA #Richmond #Indivior #SUBLOCADE #OUD

Indivior Reports Financial Results for FY and Q4 2024: Key Insights and Future Outlook Indivior PLC has released its financial results for the fiscal year and the fourth quarter of 2024, showcasing its commitment to combating substance use disorders.

Indivior Reports Financial Results for FY and Q4 2024: Key Insights and Future Outlook #United_Kingdom #pharmaceuticals #Indivior #Opioid_Treatment #Slough

Indivior Announces Delay in FDA Review of SUBLOCADE® Label Changes Amid Positive Developments Indivior PLC provides an update on the postponed FDA action date for SUBLOCADE® label changes, despite prior acceptance. Stay informed.

Indivior Announces Delay in FDA Review of SUBLOCADE® Label Changes Amid Positive Developments #USA #FDA_Approval #Richmond #Indivior #SUBLOCADE

Indivior Reshuffles Board as CFO Exits Under Oaktree Pressure Indivior (NASDAQ: INDV) said its finance chief Ryan Preblick will step down as the British drugmaker makes changes to its board following pressure from No. 2

Indivior Reshuffles Board as CFO Exits Under Oaktree Pressure

abbonews.com/business/ind...

#Indivior #Wallstreet #NYSE #NASDAQ #Stocks #StockNews #StockMarketNews #news #newsalert #BusinessNews